Zobrazeno 1 - 10
of 12
pro vyhledávání: '"35"'
Autor:
Andrew M. Will, Bryce A. Kerlin, Michael Williams, M. Sandberg Lundblad, Diane J. Nugent, C. W. Tornøe, Manuel Carcao, B. Brand-Staufer
Publikováno v:
Haemophilia. 21:380-385
Three trials investigated the pharmacokinetics (PK) of recombinant factor XIII (rFXIII) A-subunit. To compare the PK characteristics of rFXIII among trials and different age groups of patients. Dosing with rFXIII 35 IU kg(-1) every 4th week. Blood sa
Autor:
W.-Y. Wong, F. Baghaei, Darby Stephens, Thynn Thynn Yee, Robert Numerof, Anne Lienhart, Claude Negrier
Publikováno v:
Haemophilia. 19:e143-e150
Factor VIII Inhibitor Bypassing Activity (FEIBA) can effectively achieve haemostasis in haemophilia patients with inhibitors. Further evaluation of FEIBA in surgical settings is of significant interest considering the relatively limited prospective d
Autor:
Kathelijne Peerlinck, An Van Damme, Sébastien Lobet, Cedric Hermans, Kevin Deschamps, Filip Staes
Publikováno v:
Haemophilia, Vol. 26, no. 4, p. 701-710 (2020)
Haemophilia, Vol. 00, no.n-a, p. 1-10 (2020)
Haemophilia, Vol. 00, no.n-a, p. 1-10 (2020)
Introduction and aim The ankle joint remains vulnerable in children with haemophilia and is the primary joint affected. The purpose of this study was to dynamically characterize the segmental foot and ankle kinematics of male children, adolescents an
Autor:
Guillermo Cambiaggi, Egle Honorat, Ana Laura Douglas Price, Horacio Caviglia, Gustavo Galatro, Pablo Salgado
Publikováno v:
Haemophilia. 26:694-700
Introduction Haemophilic pseudotumour (HP) is an encapsulated haematoma in patients with haemophilia (PWH) which has a tendency to progress and produce clinical symptoms related to its anatomical location. Aim To show the experience of one surgeon wh
Autor:
Kingsley Hampton, Steven R. Lentz, Chunduo Shen, Elena Santagostino, Karina Meijer, Anne T. Neff, Jameela Sathar, Alberto Tosetto, Andrea Landorph, László Nemes, Pratima Chowdary
Publikováno v:
Haemophilia, 26(3), 450-458. Wiley
Haemophilia
Haemophilia
Introduction Turoctocog alfa pegol is a glycoPEGylated recombinant factor VIII (FVIII) with an extended half‐life developed for prophylaxis, treatment of bleeds and perioperative management in patients with haemophilia A. Aim Evaluate the efficacy
Autor:
Jerzy Windyga, Jin Xu, Peter Trask, Sylvia von Mackensen, Willem Bujan, Craig M. Kessler, Elena Santagostino, Midori Shima, Johannes Oldenburg, Guy Young, Rebecca Kruse-Jarres, Flora Peyvandi, Elina Asikanius, Johnny Mahlangu, Michael U. Callaghan, Claude Negrier
Publikováno v:
Haemophilia. 25:33-44
Introduction Persons with haemophilia A (PwHA) with inhibitors to factor VIII often experience decreased health-related outcomes. In HAVEN 1 (NCT02622321), there was a statistically significant reduction in bleeding with emicizumab prophylaxis versus
Autor:
A. Zakieh, A. H. Siddiqui
Publikováno v:
Haemophilia. 23:e188-e193
Introduction Patients with haemophilia are prone to medical emergencies. Emergency departments (ED) often do not have a haematologist on-call for consultation. Aim The aim of this study was to determine the utilization of ED by patients with haemophi
Publikováno v:
Haemophilia. 25
INTRODUCTION Haemophilic ankle arthropathy may cause joint bleeding, pain, stiffness, erosion and progressive motion limitations, including a decreased range of motion (ROM) secondary to anterior osteophyte impingement. AIM The purpose of this study
Autor:
J. B. de Alencar, Andressa Higa Shinzato, José Machado, Ana Maria Sell, Jeane Eliete Laguila Visentainer, M. F. de Barros, Camila Rodrigues, Luciana Conci Macedo, C. B. Pelissari
Publikováno v:
Haemophilia. 21:e312-e316
The development of factor VIII (FVIII) inhibitor is the main complication of replacement therapy in patients with haemophilia A (HA). A ratio of 5-7% of individuals HA develops antibodies (inhibitors) against the FVIII infused during the treatment, t
Autor:
L. A. Kelley, S. Karkare, Won Chan Lee, J. Powers, H. Pham, T. Wisniewski, Mitch DeKoven, David L. Cooper
Publikováno v:
Haemophilia. 20:541-549
Summary Congenital haemophilia is an inherited bleeding disorder typically diagnosed at birth or shortly thereafter. Haemophilia imposes a significant burden on patients and their caregivers. The aim of the study was to quantify the overall burden of